Analysis | QALYs | Total costs | Cost per QALY | QALYs | Total costs | Cost per QALY |
---|---|---|---|---|---|---|
 | Patients with MMSE 10-26: donepezil versus no treatment |  | Patients with MMSE 10-20: donepezil versus memantine |  | ||
Base Case | 0.146 | -€9,893 | Dominant | 0.017 | -€2,825 | Dominant |
Caregiver Time Effects of Disease Severity ↓ 25%†| 0.146 | -€9,171 | Dominant | 0.017 | -€2,608 | Dominant |
Patient Care Cost ↓ 25%‡ | 0.146 | -€6,911 | Dominant | 0.017 | -€2,417 | Dominant |
Patients institutionalized ↓ 25% | 0.135 | -€9,893 | Dominant | 0.015 | -€2,825 | Dominant |
Patient Utility Effects of Disease Severity ↓ 25% | 0.124 | -€9,893 | Dominant | 0.015 | -€2,825 | Dominant |
Stop Treatment if MMSE < 10 | 0.132 | -€11,006 | Dominant | 0.018 | -€2,279 | Dominant |
Stop Treatment if MMSE Deteriorates on any Scale after 6 Months | 0.140 | -€9,691 | Dominant | 0.054 | -€4,578 | Dominant |
5 Year Time Horizon | 0.140 | -€10,172 | Dominant | 0,016 | -€2,578 | Dominant |
Treatment Effects ↓ 25%†| 0.107 | -€5,930 | Dominant | 0.023 | -€3,379 | Dominant |
No Discontinuation | 0.204 | -€13,215 | Dominant | 0.041 | -€4,301 | Dominant |
Double Discontinuation | 0.106 | -€7,412 | Dominant | 0.003 | -€1,760 | Dominant |
Treatment Duration 5 Years | 0.140 | -€10,171 | Dominant | 0.016 | -€2,580 | Dominant |
Treatment Duration 1 Year | 0.042 | -€2,704 | Dominant | 0.008 | -€991 | Dominant |
Alternative caregiver time effect (German data)[47] | 0.146 | -€16,677 | Dominant | 0.017 | -€3,288 | Dominant |
Alternate disease severity definition based on German convention MMSE ranges * | 0.151 | -€9,486 | Dominant | 0.019 | -€3,448 | Dominant |